JP2017538722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538722A5 JP2017538722A5 JP2017532656A JP2017532656A JP2017538722A5 JP 2017538722 A5 JP2017538722 A5 JP 2017538722A5 JP 2017532656 A JP2017532656 A JP 2017532656A JP 2017532656 A JP2017532656 A JP 2017532656A JP 2017538722 A5 JP2017538722 A5 JP 2017538722A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 229910052739 hydrogen Inorganic materials 0.000 claims 44
- 239000001257 hydrogen Substances 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 43
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000003107 substituted aryl group Chemical group 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- -1 amino acid ester Chemical class 0.000 claims 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 241000709661 Enterovirus Species 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 241000709664 Picornaviridae Species 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 241000709715 Hepatovirus Species 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000005335 azido alkyl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000031976 Aquamavirus Species 0.000 claims 1
- 241000710190 Cardiovirus Species 0.000 claims 1
- 241001632249 Cosavirus Species 0.000 claims 1
- 241000146303 Coxsackievirus A1 Species 0.000 claims 1
- 241000146367 Coxsackievirus A10 Species 0.000 claims 1
- 241000146297 Coxsackievirus A11 Species 0.000 claims 1
- 241000146296 Coxsackievirus A12 Species 0.000 claims 1
- 241000146307 Coxsackievirus A13 Species 0.000 claims 1
- 241000146306 Coxsackievirus A14 Species 0.000 claims 1
- 241001429382 Coxsackievirus A16 Species 0.000 claims 1
- 241000146309 Coxsackievirus A17 Species 0.000 claims 1
- 241000146305 Coxsackievirus A19 Species 0.000 claims 1
- 241001466951 Coxsackievirus A2 Species 0.000 claims 1
- 241000146316 Coxsackievirus A20 Species 0.000 claims 1
- 241000709698 Coxsackievirus A21 Species 0.000 claims 1
- 241000146325 Coxsackievirus A3 Species 0.000 claims 1
- 241000146328 Coxsackievirus A4 Species 0.000 claims 1
- 241000146327 Coxsackievirus A5 Species 0.000 claims 1
- 241001669084 Coxsackievirus A6 Species 0.000 claims 1
- 241000146321 Coxsackievirus A7 Species 0.000 claims 1
- 241000146319 Coxsackievirus A8 Species 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000204855 Echovirus E1 Species 0.000 claims 1
- 241000709714 Echovirus E11 Species 0.000 claims 1
- 241001492221 Echovirus E12 Species 0.000 claims 1
- 241000217429 Echovirus E13 Species 0.000 claims 1
- 241000217415 Echovirus E15 Species 0.000 claims 1
- 241000217417 Echovirus E16 Species 0.000 claims 1
- 241000217419 Echovirus E17 Species 0.000 claims 1
- 241000217421 Echovirus E18 Species 0.000 claims 1
- 241000217423 Echovirus E19 Species 0.000 claims 1
- 241001492220 Echovirus E2 Species 0.000 claims 1
- 241000217425 Echovirus E20 Species 0.000 claims 1
- 241000217427 Echovirus E21 Species 0.000 claims 1
- 241000217448 Echovirus E24 Species 0.000 claims 1
- 241000190163 Echovirus E25 Species 0.000 claims 1
- 241000217449 Echovirus E26 Species 0.000 claims 1
- 241000193778 Echovirus E27 Species 0.000 claims 1
- 241000217450 Echovirus E29 Species 0.000 claims 1
- 241000217440 Echovirus E3 Species 0.000 claims 1
- 241000134257 Echovirus E30 Species 0.000 claims 1
- 241000217434 Echovirus E31 Species 0.000 claims 1
- 241000217436 Echovirus E32 Species 0.000 claims 1
- 241000217438 Echovirus E33 Species 0.000 claims 1
- 241001492209 Echovirus E4 Species 0.000 claims 1
- 241000122140 Echovirus E5 Species 0.000 claims 1
- 241000709638 Echovirus E6 Species 0.000 claims 1
- 241000201383 Echovirus E7 Species 0.000 claims 1
- 241000709643 Echovirus E9 Species 0.000 claims 1
- 241000988559 Enterovirus A Species 0.000 claims 1
- 241001529459 Enterovirus A71 Species 0.000 claims 1
- 241000988556 Enterovirus B Species 0.000 claims 1
- 241000693328 Enterovirus B69 Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000991586 Enterovirus D Species 0.000 claims 1
- 241000146324 Enterovirus D68 Species 0.000 claims 1
- 241000709691 Enterovirus E Species 0.000 claims 1
- 241000033076 Enterovirus F Species 0.000 claims 1
- 241001523584 Enterovirus G Species 0.000 claims 1
- 241001219115 Enterovirus H Species 0.000 claims 1
- 241000033074 Enterovirus J Species 0.000 claims 1
- 241000709716 Human enterovirus 70 Species 0.000 claims 1
- 241000709694 Human parechovirus 1 Species 0.000 claims 1
- 241001529465 Human parechovirus 2 Species 0.000 claims 1
- 241001474317 Human parechovirus 3 Species 0.000 claims 1
- 241001426759 Human parechovirus 4 Species 0.000 claims 1
- 241000172466 Human parechovirus 5 Species 0.000 claims 1
- 241000709701 Human poliovirus 1 Species 0.000 claims 1
- 241000709704 Human poliovirus 2 Species 0.000 claims 1
- 241000709727 Human poliovirus 3 Species 0.000 claims 1
- 241000991583 Parechovirus Species 0.000 claims 1
- 241000365416 Recovirus Species 0.000 claims 1
- 241001325464 Rhinovirus A Species 0.000 claims 1
- 241001325459 Rhinovirus B Species 0.000 claims 1
- 241001139982 Rhinovirus C Species 0.000 claims 1
- 241001333897 Sapelovirus Species 0.000 claims 1
- 241001632234 Senecavirus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094418P | 2014-12-19 | 2014-12-19 | |
| US62/094,418 | 2014-12-19 | ||
| PCT/US2015/066193 WO2016100569A1 (en) | 2014-12-19 | 2015-12-16 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538722A JP2017538722A (ja) | 2017-12-28 |
| JP2017538722A5 true JP2017538722A5 (OSRAM) | 2019-02-07 |
Family
ID=56127561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532656A Withdrawn JP2017538722A (ja) | 2014-12-19 | 2015-12-16 | 置換ヌクレオシド、ヌクレオチド、及びそのアナログ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890188B2 (OSRAM) |
| EP (1) | EP3233879A4 (OSRAM) |
| JP (1) | JP2017538722A (OSRAM) |
| CN (1) | CN107250145A (OSRAM) |
| AU (1) | AU2015364630A1 (OSRAM) |
| CA (1) | CA2970936A1 (OSRAM) |
| HK (1) | HK1245800A1 (OSRAM) |
| MA (1) | MA41213A (OSRAM) |
| MX (1) | MX2017008184A (OSRAM) |
| TW (1) | TW201625658A (OSRAM) |
| WO (1) | WO2016100569A1 (OSRAM) |
| ZA (1) | ZA201704876B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6284547B2 (ja) | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9815864B2 (en) * | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9603863B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MY190867A (en) | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| JP7125714B2 (ja) * | 2016-12-13 | 2022-08-25 | ヤマサ醤油株式会社 | 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体 |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| KR102696517B1 (ko) | 2017-09-18 | 2024-08-21 | 얀센 바이오파마, 인크. | 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체 |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| PH12021500034A1 (en) | 2019-03-06 | 2022-06-06 | Glaxosmithkline Ip No 2 Ltd | Compounds useful in hiv therapy |
| AR121356A1 (es) * | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2023073239A1 (en) | 2021-11-01 | 2023-05-04 | Immunic Ag | Medical use of n4-hydroxy citicoline compounds |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| CN114288313B (zh) * | 2022-02-18 | 2023-07-04 | 常晓宇 | 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途 |
| IL315480A (en) | 2022-03-15 | 2024-11-01 | Rome Therapeutics Inc | Compounds and methods for treating disease |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| ATE250622T1 (de) | 1999-05-12 | 2003-10-15 | Yamasa Corp | 4'-c-ethynyl-pyrimidine nukleoside |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US8513214B2 (en) * | 2007-11-09 | 2013-08-20 | The United States Of America As Represented By The Secretary Of The Dept. Of Health And Human Services | C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| WO2010030858A1 (en) * | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
| EP2623104A1 (en) | 2009-03-20 | 2013-08-07 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| WO2010132513A1 (en) * | 2009-05-12 | 2010-11-18 | Southern Research Institute | 2'-fluoro arabino nucleosides and use thereof |
| CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| AU2011349278C1 (en) | 2010-12-22 | 2017-01-19 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| HK1203513A1 (en) | 2012-03-21 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Methods of preparing substituted nucleotide analogs |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG10201804571TA (en) | 2012-03-21 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6284547B2 (ja) | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
| WO2014164533A1 (en) | 2013-03-11 | 2014-10-09 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9815864B2 (en) | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3055319A4 (en) * | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AR099312A1 (es) * | 2014-02-06 | 2016-07-13 | Riboscience Llc | Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US9603863B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| BR112016029994A2 (pt) | 2014-06-24 | 2017-08-22 | Alios Biopharma Inc | métodos de preparação de análogos de nucleotídeo substituídos |
| CN106573011A (zh) * | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
| US20160022724A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| WO2016022464A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
-
2015
- 2015-12-15 MA MA041213A patent/MA41213A/fr unknown
- 2015-12-16 MX MX2017008184A patent/MX2017008184A/es unknown
- 2015-12-16 US US14/971,926 patent/US9890188B2/en not_active Expired - Fee Related
- 2015-12-16 JP JP2017532656A patent/JP2017538722A/ja not_active Withdrawn
- 2015-12-16 CN CN201580076647.5A patent/CN107250145A/zh active Pending
- 2015-12-16 CA CA2970936A patent/CA2970936A1/en not_active Abandoned
- 2015-12-16 EP EP15871022.8A patent/EP3233879A4/en not_active Withdrawn
- 2015-12-16 WO PCT/US2015/066193 patent/WO2016100569A1/en not_active Ceased
- 2015-12-16 AU AU2015364630A patent/AU2015364630A1/en not_active Abandoned
- 2015-12-16 HK HK18105072.0A patent/HK1245800A1/zh unknown
- 2015-12-18 TW TW104142822A patent/TW201625658A/zh unknown
-
2017
- 2017-07-18 ZA ZA2017/04876A patent/ZA201704876B/en unknown
-
2018
- 2018-01-30 US US15/884,052 patent/US20180155384A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538722A5 (OSRAM) | ||
| JP2016506960A5 (OSRAM) | ||
| JP2016523906A5 (OSRAM) | ||
| CY1121161T1 (el) | Εξαμελες παραγωγο πυρρολιου ετεροαρυλικου δακτυλιου, μεθοδος παρασκευης αυτου και ιατρικες χρησεις αυτου | |
| JP2012511588A5 (OSRAM) | ||
| EA200901573A1 (ru) | Гетероарилзамещенные тиазолы | |
| JP2016506962A5 (OSRAM) | ||
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| NZ631738A (en) | (hetero) arylacetamide derivatives as antiretroviral agents | |
| TN2012000399A1 (en) | Dihydrofuran derivatives as insecticidal compounds | |
| WO2012174312A3 (en) | Benzimidazole derivatives as antiviral agents | |
| JP2014506599A5 (OSRAM) | ||
| RU2017123114A (ru) | 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов | |
| JP2016540742A5 (OSRAM) | ||
| NZ631762A (en) | 5-membered heteroaryls and their use as antiviral agents | |
| JP2014521688A5 (OSRAM) | ||
| UA117800C2 (uk) | Похідні урацилу або тиміну для лікування гепатиту с | |
| HRP20191444T1 (hr) | Alosterni modulatori proteina jezgre hepatitisa b | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| JP2013508373A5 (OSRAM) | ||
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| JP2016517417A5 (OSRAM) | ||
| HRP20160083T1 (hr) | Makrocikliäśki inhibitori serinske proteaze virusa hepatitisa c izvedeni iz prolina | |
| NZ593712A (en) | Intermediates for synthesising nucleoside aryl phosphoramidates |